Back to top

LACOG 1018 – PALBO in Ovarian Cancer

  /    /  LACOG 1018 – PALBO in Ovarian Cancer

Palbociclib plus letrozole combination after progression to second line chemotherapy for women with ER/PR-positive ovarian cancer

Type of Study: Clinical Trial

Sponsor / Support: LACOG

Primary Objectives: To evaluate the efficacy, assessed by 12 weeks progression-free survival (PFS), of Palbociclib plus Letrozole in ER/PR positive serous ovarian cancer that progressed on second line chemotherapy.

Design: Multicenter, single arm, phase II clinical trial.

Sample Size: 39 patients

Principal Investigator: Fernanda Bronzon Damian

Countries LATAM: Brazil